^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    albumin-bound paclitaxel

    i
    Other names: ABI007, ABI-007, SNA-001, HC007
    Company:
    Generic mfg.
    Drug class:
    Tubulin inhibitor
    Related drugs:
    23h
    KEYNOTE A99: Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) (clinicaltrials.gov)
    P1/2, N=296, Active, not recruiting, Inhibrx Biosciences, Inc | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden)
    |
    EGFR mutation • TMB-H • MSI-H/dMMR • ALK rearrangement
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • ordastobart (INBRX-106)
    2d
    Moxifloxacin in Adjuvant Treatment of Patients With Operable Breast Cancer (clinicaltrials.gov)
    P3, N=559, Completed, Sun Yat-sen University | Recruiting --> Completed
    Trial completion
    |
    docetaxel • doxorubicin hydrochloride • albumin-bound paclitaxel • cyclophosphamide
    2d
    TransStar101: A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=150, Active, not recruiting, Suzhou Transcenta Therapeutics Co., Ltd. | Trial completion date: Sep 2025 --> Nov 2026 | Trial primary completion date: May 2025 --> May 2026
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • leucovorin calcium • osemitamab (TST001)
    2d
    Complete remission of recurrent human papillomavirus-associated cervical cancer managed with camrelizumab and nanoparticle albumin-bound paclitaxel as second-line treatment: a case report. (PubMed, Front Immunol)
    The current therapeutic protocols outlined in the National Comprehensive Cancer Network Guidelines 4.2025 edition propose that for second-line or subsequent therapies of cervical carcinoma, prioritized protocols incorporate pembrolizumab administration specifically for patients demonstrating high tumor mutational burden characteristics, positive for programmed cell death ligand 1 expression, or exhibiting microsatellite instability-high/mismatch repair deficiency molecular profiles. Other proposed therapeutic approaches include bevacizumab, paclitaxel, and nanoparticle albumin-bound paclitaxel (nab-paclitaxel)...The patient continues to undergo active clinical surveillance. Our case report illustrates that second-line immunochemotherapy utilizing camrelizumab in combination with nab-paclitaxel exhibits notable efficacy and manageable safety profile.
    Journal • Tumor mutational burden • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
    |
    TMB-H • MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • AiRuiKa (camrelizumab) • albumin-bound paclitaxel
    2d
    The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Treatment for Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=25, Recruiting, Hebei Medical University Fourth Hospital
    New P2 trial
    |
    cisplatin • albumin-bound paclitaxel • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    2d
    A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies (clinicaltrials.gov)
    P1/2, N=252, Recruiting, Bristol-Myers Squibb | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • gemcitabine • albumin-bound paclitaxel
    3d
    Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis (clinicaltrials.gov)
    P2, N=40, Recruiting, Mayo Clinic | Trial completion date: May 2027 --> Jul 2029 | Trial primary completion date: May 2026 --> Jul 2029
    Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    cisplatin • albumin-bound paclitaxel • mitomycin
    3d
    Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer (clinicaltrials.gov)
    P2, N=23, Completed, Emory University | Active, not recruiting --> Completed
    Trial completion
    |
    gemcitabine • albumin-bound paclitaxel • Xermelo (telotristat etiprate)
    3d
    BRICES: QL1706 Plus Chemotherapy for Borderline Resectable Esophageal Cancer (clinicaltrials.gov)
    P2, N=24, Not yet recruiting, Ruijin Hospital
    New P2 trial
    |
    cisplatin • albumin-bound paclitaxel • Qibeian (iparomlimab/tuvonralimab)
    3d
    QL1706 Plus Chemotherapy as Neoadjuvant Therapy for Locally Advanced Cervical Cancer: A Phase II Trial (clinicaltrials.gov)
    P2, N=50, Recruiting, Affiliated Cancer Hospital & Institute of Guangzhou Medical University
    New P2 trial
    |
    cisplatin • carboplatin • albumin-bound paclitaxel • Qibeian (iparomlimab/tuvonralimab)
    3d
    A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, M.D. Anderson Cancer Center
    New P2 trial
    |
    gemcitabine • albumin-bound paclitaxel • oxaliplatin • irinotecan • BMS‐986504
    3d
    Phase II Trial of Albumin-Bound Paclitaxel Combined With Nedaplatin (TP) Via Hepatic Arterial Infusion for Advanced Breast Cancer Patients With Liver Metastases After Failure of Standard Therapy (clinicaltrials.gov)
    P2, N=30, Recruiting, Zhejiang Cancer Hospital
    New P2 trial
    |
    albumin-bound paclitaxel • Aqupla (nedaplatin)